Presentations & Publications

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- D28 sTTR association with CVMCVH

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis

PRESENTATION · Nov 2025 · PDF

Acoramidis -AHA 2025- NT-proBNP and Atrial Fibrillation

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- ACM and CVH (early HF with and without AF)

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- VA Prevalence Geographic Disparities

PRESENTATION · Nov 2025 · PDF

Acoramidis-AHA 2025- Demographic Disparities

PRESENTATION · Sep 2025 · PDF

Acoramidis-HFSA-2025-VA-Incidence-of-ATTR-CM-by-State

PRESENTATION · Sep 2025 · PDF

Acoramidis-HFSA-2025-Effect-on-CVM_Recurrent-CVH-Cumulative-Incidence-Oral-Presentation

PRESENTATION · Sep 2025 · PDF

Acoramidis-HFSA-2025-Cardiac-Conduction-abnormalities

PRESENTATION · Aug 2025 · PDF

BBIO - Acoramidis TTR - ESC 2025 - Stable/Improved NAC at Month 30

PUBLICATION · May 2025 · PDF

Journal of the American College of Cardiology, Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - PNS 2025 - Low Transthyretin Is Associated With Severe Comorbidities

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis AG10 TTR - ESC-HF 2025 - Disease Progression Among Patients for ATTR-CM in a Real-world Setting

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Time from First Recorded Clinical Manifestation to Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using U.S. Claims Data

PRESENTATION · May 2025 · PDF

BBIO - Acoramidis TTR - ESC-HF 2025 - Cause of Death in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from ATTRibute-CM

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Addition of Another TTR Stabilizer Did Not Further Increase Serum TTR Levels

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Pre-specified NT-proBNP Sensitivity Analyses

PRESENTATION · Apr 2025 · PDF

Acoramidis TTR - ACC 2025 - Improvements in NYHA Class at Month 30 Versus Placebo

PRESENTATION · Mar 2025 · PDF

BBIO - Acoramidis TTR - ACC 2025 - Pre-specified Sensitivity Analyses Addressed Use of Another TTR Stabilizer in ATTRibute-CM

PRESENTATION · Mar 2025 · PDF

Acoramidis TTR - ACC 2025 -Healthcare Disparities and Diagnostic Trends

PUBLICATION · Mar 2025 · PDF

Journal of the American College of Cardiology, Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy

PUBLICATION · Mar 2025 · PDF

Circulation, Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report from the Open-Label Extension of the ATTRibute-CM Trial

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Acoramidis reduces ACM and CVH: initial outcomes from the ATTRibute-CM open label extension study

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Costs and healthcare resource utilization in ATTR-CM exceeds that of non-amyloid heart failure

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Evolving baseline risk in patients with ATTR-CM: a systematic literature review of clinical trials

PRESENTATION · Dec 2024 · PDF

Acoramidis - AHA 2024 - Relationship between CVH and survival in the acoramidis-treated participants within ATTRibute-CM

PRESENTATION · Dec 2024 · PDF

Acoramidis - HFSA 2024 - ATTRibute-CM Post Hoc Recurrent Event Analyses

PRESENTATION · Dec 2024 · PDF

Acoramidis - ESC 2024 - Increase in Serum TTR Levels Observed With Acoramidis Treatment in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension

PRESENTATION · Dec 2024 · PDF

Acoramidis - ISA 2024 - Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ISA 2024 - Higher risk of mortality in previously hospitalized patients

PRESENTATION · Dec 2024 · PDF

Acoramidis - ISA 2024- Featured research in the ATTR-CM landscape

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - EQ-5D Analysis from the ATTRibute-CM Study

PRESENTATION · Dec 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - NT-proBNP Insights from the ATTRibute-CM Study

PUBLICATION · Dec 2024 · PDF

Circulation: Heart Failure, Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy

PRESENTATION · Dec 2024 · PDF

PRESENTATION · Nov 2024 · PDF

BBIO - Acoramidis - ESC Heart Failure 2024 - ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD in ATTRibute-CM

PRESENTATION · Nov 2024 · PDF

BBIO - Acoramidis - ACC 2024 - CMR Imaging Substudy from ATTRibute-CM Phase 3 Study

PUBLICATION · Jan 2024

The New England Journal of Medicine, Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

PRESENTATION · Dec 2023 · PDF

Acoramidis - AHA 2023 - Clinical Outcome Improvements

PRESENTATION · Dec 2023 · PDF

Acoramidis - October 2023 - 4 Year Update from OLE Phase 2 Study

PRESENTATION · Dec 2023 · PDF